COSMOS CHOUZAI Pharmacy Co.,Ltd.

COSMOS CHOUZAI Pharmacy Co.,Ltd.

309A.T
COSMOS CHOUZAI Pharmacy Co.,Ltd.JP flagTokyo Stock Exchange
700.00
JPY
- -
- -
2.12BMarket Cap
2023 Y
2024 Y
2025 Y
2026 Y
Revenue per Share
1,918.68
2,045.29
2,080.33
- -
Basic EPS, GAAP
6.28
8.93
45.62
- -
Free Cash Flow per Basic Share
27.44
98.18
-10.25
- -
Dividend per Share
- -
- -
- -
- -
Book Value per Share
154.38
307.44
353.39
388.76
Tangible Book Value per Share
41.65
235.37
258.18
300.5
Basic Weighted Avg Shares
3
3
3
- -
Sales/Revenue/Turnover
5,804
6,187
6,293
6,511
Operating Margin (%)
1.74
5.16
3.99
3.81
Depreciation Expense
143
145
126
129
Net Income, GAAP
19
27
138
176
Effective Tax Rate (%)
21.28
52.68
42.91
27.31
Profit Margin (%)
0.33
0.44
2.19
2.7
Working Capital
738
929
784
693
LT Debt
901
806
700
526
Total Equity
834
930
1,069
1,176
Return on Invested Capital (%)
- -
7.5
7.29
9.37
Return on Capital (%)
- -
-1.82
7.53
9.68
Return on Common Equity (%)
- -
3.87
13.81
15.68

Capital Structure

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
10.01%
Free Cash Flow
- -
- -
-758.06%
Net Income, GAAP
- -
- -
27.54%
Sales/Revenue/Turnover
- -
- -
3.46%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
6,187
2025
- -
- -
- -
- -
6,293
2026
- -
- -
- -
- -
6,511

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
8.93
2025
- -
- -
- -
- -
45.62
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

APIChatGPT
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Address
Hanaguruma Building, North Wing Nagoya AI Japan 450-0002
IPO Date
Jan 8, 2025
Business
Cosmos Chouzai Pharmacy Co., Ltd. is a Japan-based pharmaceutical retailer and wholesaler that specializes in the distribution, sale, and management of medicines and related products to healthcare providers and consumers. The company focuses on pharmaceutical products, over-the-counter medications, health and wellness items, and related healthcare services, delivered through its network of pharmacies and distribution channels. Main products and services: prescription medicines; over-the-counter drugs; medical supplies and consumables; health and wellness products; pharmaceutical distribution and logistics; store-front retail operations; health consultation and pharmacy services; patient support programs; e-commerce and online pharmacy services; hospital and clinic supply contracts; wholesale distribution to drugstores and medical facilities; private-label and branded pharmaceutical products where applicable; regulatory compliance and quality assurance programs. Latest major company changes: strategic partnerships and alliances within the pharmaceutical distribution ecosystem; expansions of retail footprint and pharmacy networks; potential acquisitions or mergers within the local and regional pharmacy sector; new product lines or service offerings such as digital health services or online pharmacy platforms; corporate reorganizations to optimize supply chain efficiency and expand geographic reach; initiatives to enhance operational efficiency and regulatory compliance in response to evolving healthcare regulations. Additional context: industry and business segments include pharmaceutical retail, wholesale distribution, and healthcare services; target markets comprise hospitals, clinics, community pharmacies, and individual consumers within Japan and potentially neighboring regions; geographic operations are centered in Japan with distribution capabilities to national networks; founded year and headquarters location are in Japan, with the company operating its primary stores and distribution facilities domestically; subsidiaries or parent company relationships may exist within a larger corporate group or affiliated entities in the pharmaceutical distribution sector.